Absorption profile and absolute bioavailability of a theophylline sustained release preparation

被引:0
|
作者
Pabst, G [1 ]
Weber, W [1 ]
Barkworth, MF [1 ]
Müller, M [1 ]
Rehm, KD [1 ]
机构
[1] LAB Gesell Pharmakol Untersuchungen mbH, Neu Ulm, Germany
来源
ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH | 1998年 / 48卷 / 5A期
关键词
antiasthmatics; Bronchoretard (R); CAS; 58-55-9; theophylline; bioavailability; clinical pharmacokinetics; sustained release;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In a single-dose crossover study with 16 healthy male nonsmoking volunteers the absorption profile and absolute bioavailability of the sustained release pellets contained in all dosage strengths of Bronchoretard(R) (100, 200, 350, 500 mg anhydrous theophylline) were investigated. One capsule (500 mg theophylline) was given after an evening meal. The reference treatment consisted of an i.v. infusion over 8 h in a total dosage of 350 mg theophylline. Plasma concentration-time profiles were evaluated for 72 h after dosing, respectively start of infusion. Theophylline was measured by high-performance liquid chromatography (HPLC). Absorption profiles (Wagner-Nelson) were derived and the absolute bioavailability was calculated. For the sustained release pellets a liberation/absorption of zero order for 12 h could be noted; the dose-corrected mean absolute bioavailability was 88 %. The assumptions of an investigation on absolute bioavailability are discussed and the limitations on generalizability resulting therefrom.
引用
收藏
页码:574 / 579
页数:6
相关论文
共 50 条
  • [1] INFLUENCE OF FOOD ON THE BIOAVAILABILITY OF THEOPHYLLINE FROM A SUSTAINED-RELEASE THEOPHYLLINE PREPARATION
    LOHMANN, A
    DINGLER, E
    SOMMER, W
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1991, 41-2 (07): : 732 - 734
  • [2] Pharmacokinetics of a sustained release theophylline preparation in young asthmatics
    Witschital, K
    Fuchs, WS
    Heese, U
    von Nieciecki, A
    Laicher, A
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 1998, 48 (5A): : 593 - 596
  • [3] Comparative bioavailability of theophylline from tablets with different sustained release kinetics
    ElSayed, G
    ElSaid, Y
    Meshali, M
    Schwartz, JB
    STP PHARMA SCIENCES, 1996, 6 (06): : 398 - 402
  • [4] In vivo verification of the in vitro release specification of a sustained release theophylline preparation
    von Nieciecki, A
    Fuchs, WS
    Pabst, G
    Müller, M
    Dilger, C
    Gay, S
    Laicher, A
    Stanislaus, F
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 1998, 48 (5A): : 580 - 583
  • [5] Effect of cholagogia on the pharmacokinetic profile of a sustained release theophylline formulation
    Fuchs, WS
    von Nieciecki, A
    Molz, KH
    Popescu, G
    Weil, A
    Barkworth, MF
    Gay, S
    Laicher, A
    Stanislaus, F
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 1998, 48 (5A): : 597 - 604
  • [6] Effect of pretreatment with ranitidine on the pharmacokinetics and gastrointestinal transit of a sustained release theophylline preparation
    Wilson, CG
    Washington, N
    Greaves, JL
    Blackshaw, PE
    Perkins, AC
    Barkworth, MF
    Rehm, KD
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 1998, 48 (5A): : 561 - 568
  • [7] Relative bioavailability and bioequivalence study of theophylline sustained release formulations
    Vergin, H
    Mahr, G
    Winterhalter, B
    Wigand, R
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2003, 53 (09): : 635 - 639
  • [8] EVALUATION OF THE EFFECT OF DIFFERENT KINDS OF FOODS ON THE BIOAVAILABILITY OF A SUSTAINED-RELEASE THEOPHYLLINE TABLET
    GAI, MN
    THIELEMANN, AM
    ARANCIBIA, A
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1993, 31 (11) : 547 - 552
  • [9] STUDY ON THE INFLUENCE OF FOOD ON THE ABSORPTION OF THEOPHYLLINE FROM A CONTROLLED-RELEASE PREPARATION
    PABST, G
    WEBER, W
    MULLER, M
    BARKWORTH, MF
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1994, 44-1 (03): : 333 - 337
  • [10] Anti-inflammatory efficacy of theophylline administered as a sustained release preparation - Results of a pilot study with low-dose theophylline
    Bodner, A
    Hens, C
    Moser, C
    Oster, H
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 1998, 48 (5A): : 617 - 624